ArticleJournal of translational medicine2019

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.

Apostolos Sarivalasis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.